Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report.
10.7499/j.issn.1008-8830.2412050
- Author:
Ping YI
1
;
Xing-Xing ZHANG
1
;
Tian TANG
1
;
Ying WANG
1
;
Xiao-Chuan WU
1
;
Xing-Fang LI
1
Author Information
1. Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
- Publication Type:English Abstract
- Keywords:
Castleman disease;
Siltuximab;
TAFRO syndrome;
Tocilizumab
- MeSH:
Humans;
Castleman Disease/drug therapy*;
Child;
Antibodies, Monoclonal, Humanized/administration & dosage*;
Female;
Antibodies, Monoclonal/administration & dosage*
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(5):613-617
- CountryChina
- Language:Chinese
-
Abstract:
The patient, an 11-year-old girl, was admitted with recurrent fever for 20 days, worsening with abdominal distension for 7 days. Upon admission, she presented with recurrent fever, lymphadenopathy, hepatosplenomegaly, polyserositis, and multiple organ dysfunction. Lymph node pathology and clinical manifestations confirmed the diagnosis of idiopathic multicentric Castleman disease-TAFRO syndrome. Treatment with siltuximab combined with glucocorticoids was initiated, followed by maintenance therapy with tocilizumab. The patient is currently in complete clinical remission. Therefore, once a child is diagnosed with idiopathic multicentric Castleman disease -TAFRO syndrome, early use of siltuximab should be considered for rapid disease control, followed by tocilizumab for maintenance therapy.
